Nebivolol Mylan (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebivolol Mylan, is a Beta‑blocker (selective β1‑adrenergic antagonist) presented as an oral tablet for oral use. It treats hypertension and heart failure with reduced ejection fraction in adult patients.

GNH USA supplies Nebivolol Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is indicated for cardiovascular conditions that benefit from selective β1‑adrenergic blockade and vasodilation.

- Hypertension: lowers elevated blood pressure and reduces cardiovascular risk. - Heart failure (reduced ejection fraction): improves ventricular function and decreases mortality. - Hypertension in patients with diabetes: provides blood‑pressure control while offering additional nitric‑oxide‑mediated vasodilatory effects.

Nebivolol may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild to moderate pain often transient. - Dizziness or light‑headedness: especially on standing. - Fatigue or tiredness: reduced energy levels. - Bradycardia: slower than normal heart rate. - Nausea: occasional stomach upset. - Cough: dry or mild irritation.

Serious or Rare Side Effects: - Severe bradycardia or heart block: may require medical attention. - Acute bronchospasm: especially in patients with asthma. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Marked hypotension: sudden drop in blood pressure. - Hepatic enzyme elevation: abnormal liver function tests. - Heart failure decompensation: worsening symptoms in susceptible individuals.

Before initiating Nebivolol, clinicians should evaluate several safety considerations.

- Cardiovascular assessment: review heart rate, rhythm, and conduction abnormalities. - Bronchospastic disease: use cautiously in asthma or COPD patients. - Diabetes mellitus: monitor blood‑glucose as β‑blockade may mask hypoglycaemia signs. - Renal or hepatic impairment: consider dose adjustment or close monitoring. - Pregnancy and lactation: limited data; avoid unless clearly needed. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Other beta‑blockers: additive bradycardia and hypotension. - Calcium‑channel blockers (verapamil, diltiazem): increased risk of AV‑block. - Strong CYP2D6 inhibitors (paroxetine, fluoxetine): elevated nebivolol plasma levels.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance antihypertensive effect, requiring BP monitoring. - NSAIDs: can blunt blood‑pressure‑lowering response. - Insulin or oral hypoglycemics: β‑blockade may mask hypoglycaemia symptoms, necessitating glucose checks.